Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

9.38USD
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
$9.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,017
52-wk High
$21.35
52-wk Low
$8.62

Chart for

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 2.21
Market Cap(Mil.): $1,257.42
Shares Outstanding(Mil.): 67.79
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -2.06 -- --
ROI: -51.70 0.63 14.31
ROE: -59.18 1.68 16.04

BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49

* EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

May 08 2018

BRIEF-Epizyme Provides Update Regarding Tazemetostat Clinical Program

* EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM

Apr 23 2018

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥10,530 +70.00
Novartis AG (NOVN.S) CHF84.28 +0.20
GlaxoSmithKline plc (GSK.L) 1,494.40 +8.40
Celgene Corporation (CELG.OQ) $84.40 +0.12

Earnings vs. Estimates